MedTrace Logo

Seroquel XR in Adults With Schizophrenia

NCT00852631 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-07-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally given, up to 600 mg once a day for 42 days.

Conditions

Interventions

DRUG

Quetiapine fumarate (Seroquel)

600mg Extended release tablet, oral, once daily

Sponsors & Collaborators

Principal Investigators

  • Thawatchai Leelahanaj, MD · Phramongkutklao Hospital, Bangkok, Thailand

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00852631 on ClinicalTrials.gov